

IN THE CLAIMS:

1-37. (Canceled)

38. (Previously presented) A composition comprising modified GPI molecule or derivative or equivalent thereof which induces an immune response directed to a micro-organism GPI inositolglycan domain but is incapable of inducing an immune response directed to a lipidic domain of said GPI.

39-53. (Canceled)

54. (Previously presented) A composition according to claim 38, wherein said modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipid domain.

55. (Previously presented) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (Previously presented) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (Previously presented) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (Previously presented) A composition according to claim 57, wherein said Plasmodium is *P. falciparum*.

59. (Currently amended) A composition according to claim ~~54 or 58~~ 55, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Man α 1,2)-Man α 1,2 Man α 1,6 Man α 1,4 GlcN-myo-inositol phosphoglycerol or a derivative or equivalent

thereof.

60. (Currently amended) A composition according to claim ~~54 or 58~~ 55, wherein said GPI inositolglycan domain comprises the structure

X1-X2-X3-X4-ethanolamine-phosphate-(Man α 1,2)-Man α 1,2Man α 1,6Man α 1,4GlcN-myoinositol phosphoglycerol

wherein X1, X2, X3 and X4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

61. (Currently amended) A composition according to claim ~~54 or 58~~ 55, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[Ma2]Ma2 Ma 6 Ma4Ga6Ino
EtN-P-[Ma2][G]Ma2 Ma6 Ma4Ga6Ino
EtN-P-[Ma2][X]Ma2Ma6Ma4Ga6Ino
EtN-P-[Ma2][EtN-P]Ma2Ma6 Ma4Ga6Ino
EtN-P-Ma2 Ma6 Ma4G
Ma2 Ma6 MaG
EtN-P-Ma2 Ma6 M
EtN-P-[Ma2][G]Ma2 Ma6 Ma4G
EtN-P-[Ma2][X]Ma2 Ma6 Ma4G
EtN-P-[Ma2][EtN-P]Ma2 Ma6 Ma4G
Ma2 [Ma2][G]Ma2 Ma6 Ma4G
Ma2 [Ma2][X]Ma2 Ma6 Ma4G
Ma2 [Ma2][EtN-P]Ma6 Ma4G
Ma6 Ma4Ga6Ino
Ma2 Ma6 Ma4Ga6Ino
Ma2 [Ma2]Ma6 Ma4Ga6Ino
Ma2 [Ma2][G]Ma6 Ma4Ga6Ino
Ma2 [Ma2][X]Ma6 Ma4Ga6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M
 EtN-P-[Mα2][X]Mα2 Mα6 M
 EtN-P-[Mα2][EtN-P]Mα2 Mα6 M
 Mα2 [Mα2][G]Mα2 Mα6 M
 Mα2 [Mα2][X]Mα2 Mα6 M
 Mα2 [Mα2][EtN-P]Mα6 M
 Mα2 Mα6 M
 Mα6 Mα4G
 EtN-P-[Mα2] [G]Mα2 M
 EtN-P-[Mα2][X]Mα2 M
 EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.